DescriptionCurator's Comment: Description was created based on several sources, including https://www.springboard4health.com/notebook/v_e.html and http://www.ncbi.nlm.nih.gov/pubmed/2134664
Curator's Comment: Description was created based on several sources, including https://www.springboard4health.com/notebook/v_e.html and http://www.ncbi.nlm.nih.gov/pubmed/2134664
Tocopherol (alpha tocopheryl nicotinate) is an ester of tocopherol and nicotinic acid. Vitamin E (Tocopherol) is sold commercially as the esterified form (alpha tocopheryl acetate, alpha tocopheryl succinate and alpha tocopheryl nicotinate). Alpha tocopheryl nicotinate has antioxidant and vasodilatory properties. It can be used as a mild warming agent, without producing the redness typical for nicotinic acid. Tocopherol (alpha tocopheryl nicotinate) has been available in Japan since 1967. Tocopherol under the brand name Juvela N is approved in Japan for the treatment of symptoms accompanying hypertension, hyperlipidemia, peripheral circulatory disturbance resulting from arteriosclerosis obliterans. Tocopherol has being shown to inhibit platelet aggregation.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0070527 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2134664 |
|||
Target ID: GO:0070527 |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Juvela N Approved UseAccompanying symptoms resulting from the following
Hypertension
Hyperlipidemia
Peripheral circulatory disturbance resulting from the following
Arteriosclerosis obliterans Launch Date1966 |
|||
| Primary | Juvela N Approved UseAccompanying symptoms resulting from the following
Hypertension
Hyperlipidemia
Peripheral circulatory disturbance resulting from the following
Arteriosclerosis obliterans Launch Date1966 |
|||
| Primary | Juvela N Approved UseAccompanying symptoms resulting from the following
Hypertension
Hyperlipidemia
Peripheral circulatory disturbance resulting from the following
Arteriosclerosis obliterans Launch Date1966 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| UPLC method for the determination of vitamin E homologues and derivatives in vegetable oils, margarines and supplement capsules using pentafluorophenyl column. | 2014-12 |
|
| Final report on the safety assessment of Tocopherol, Tocopheryl Acetate, Tocopheryl Linoleate, Tocopheryl Linoleate/Oleate, Tocopheryl Nicotinate, Tocopheryl Succinate, Dioleyl Tocopheryl Methylsilanol, Potassium Ascorbyl Tocopheryl Phosphate, and Tocophersolan. | 2002 |
|
| A family of familial hypercholesterolemia with cerebral infarction and without coronary heart disease. An unusual case with corneal opacity, polyneuropathy and carpal tunnel syndrome in the family: therapy with probucol and tocopherol nicotinate. | 1991-11 |
Patents
Sample Use Guides
The usual adult dosage for oral use is 300 - 600 mg of
tocopherol nicotinate (3 - 6 capsules) daily in three divided
doses
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/835137
177 uM of Tocopherol led to decreased human platelet aggregation in response to the combined ADP and H2O
2
| Substance Class |
Mixture
Created
by
admin
on
Edited
Mon Mar 31 19:04:51 GMT 2025
by
admin
on
Mon Mar 31 19:04:51 GMT 2025
|
| Record UNII |
R0ZB2556P8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QA11HA03
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
||
|
WHO-ATC |
A11HA03
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
||
|
LOINC |
29747-3
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
||
|
LOINC |
87672-2
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
||
|
LOINC |
47791-9
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
||
|
LOINC |
59250-1
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
||
|
LOINC |
74544-8
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000077035
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
PRIMARY | |||
|
1236136
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID8021357
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
PRIMARY | |||
|
R0ZB2556P8
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
PRIMARY | |||
|
CHEMBL47
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
PRIMARY | |||
|
1406-66-2
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
PRIMARY | |||
|
SUB15582MIG
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
PRIMARY | |||
|
C68313
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
PRIMARY | |||
|
DB11251
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
PRIMARY | |||
|
SUB15583MIG
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
ALTERNATIVE | |||
|
D024505
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
PRIMARY | |||
|
R0ZB2556P8
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
PRIMARY | |||
|
27013
Created by
admin on Mon Mar 31 19:04:51 GMT 2025 , Edited by admin on Mon Mar 31 19:04:51 GMT 2025
|
PRIMARY |
All of the following components must be present:
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |